Tagraxofusp-erzs - Biologic Drug Details

Summary for tagraxofusp-erzs

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for tagraxofusp-erzs

Mechanism of Action	CD123 Interactions
Established Pharmacologic Class	CD123 Interaction Cytotoxin
Chemical Structure	Cytotoxins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tagraxofusp-erzs Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tagraxofusp-erzs Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tagraxofusp-erzs Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Tagraxofusp-erzs

Last updated: March 1, 2026

What is Tagraxofusp-erzs?

Tagraxofusp-erzs (brand name: Elzonris) is a biologic drug indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It is a fusion protein composed of interleukin-3 (IL-3) fused to a truncated diphtheria toxin, targeting the CD123 antigen expressed on BPDCN cells.

Market Size and Unmet Need

BPDCN is a rare hematologic malignancy with an incidence rate of approximately 0.04 to 0.1 cases per million annually (Fournier et al., 2021). The lack of approved therapies prior to Elzonris's approval in 2018 limited treatment options, primarily relying on intensive chemotherapy and stem cell transplant, with median survival around 12–14 months. The drug represents a targeted therapy addressing an unmet medical need in a rare disease.

Regulatory Milestones

• FDA Approval: April 2018 for BPDCN in adults (FDA, 2018)

• EMA Status: Conditional approval in the European Union granted in 2020 (EMA, 2020)

• Designations: Orphan drug designation in U.S. and EU; breakthrough therapy designation in the U.S.

Market Dynamics

Competitive Landscape

Elzonris remains the first and only FDA-approved drug specifically targeting BPDCN. Its main competitors are:

• Chemotherapy regimens, including hyper-CVAD and other multi-agent protocols.
• Stem cell transplantation, suitable for eligible patients.
• Investigational agents such as anti-CD123 monoclonal antibodies (e.g., CD123 CAR-T therapy), but none are approved.

Adoption Rate Drivers

• Rare disease status: Limits overall population but heightens per-patient treatment value.
• Clinical efficacy: ORR (overall response rate) of 75% in clinical trials; median duration of response (DOR) around 2.5–4.5 months (Wang et al., 2019).
• Safety profile: manageable adverse events, primarily capillary leak syndrome and elevated liver enzymes.

Access and Reimbursement

Reimbursement policies vary by country. In the U.S., Medicare and insurers typically cover the drug under rare disease pathways. In Europe, reimbursement remains limited due to cost and the small patient population.

Pricing and Revenue

• List price: Approximately $23,000 per infusion in the U.S. (Red Book, 2023).
• Dosing: Based on patient weight, typically 12 mcg/kg IV infusion over 15 minutes on days 1–3 of each 21-day cycle.
• Revenue Estimates: In 2022, U.S. sales surpassed $50 million, reflecting limited penetration primarily due to market size, with potential growth if awareness and off-label use increase.

Market Penetration Challenges

• Small patient population constrains total revenue.
• Limited evidence from pivotal trials, characterized as phase II, restricts broader indication approval.
• Investment in off-label use and combination therapies remains unofficial and under-studied.

Financial Trajectory

Revenue Projections

• Short-term outlook (2023–2025): Moderate growth driven by increased diagnosis and clinician familiarity.
• Long-term potential: Modest expansion contingent on expanding indications, such as other CD123-positive hematologic malignancies.

R&D and Wind-Down Risks

• Limited pipeline; no approved follow-up therapies.
• Competitive developments in the CD123-targeted space could outpace Elzonris if superior agents emerge.
• Biosimilar entry is unlikely given the biologic's orphan status and patent protections.

Patent and Pricing Landscape

• Patents extend until 2030, providing market exclusivity.
• Pricing strategies focus on high per-patient value, with drug costs justified by limited alternatives and high treatment specificity.

Conclusion

Tagraxofusp-erzs's market extends primarily within the orphan drug segment, with revenues constrained by disease rarity but sustained by high treatment costs and regulatory exclusivity. Growth potential relies on improved awareness, clinical efficacy data, and potential indication expansion. Investment in this asset benefits from a clear regulatory and patent landscape but faces challenges from the small patient pool and emerging therapies.

Key Takeaways

• Elzonris is the only approved biologic for BPDCN, a rare but aggressive disease.
• The drug's revenue is limited; in 2022, U.S. sales exceeded $50 million.
• Market penetration will depend on clinician adoption, reimbursement, and evidence expansion.
• Patent protection lasts until 2030, supporting exclusivity.
• The overall treatment landscape remains limited but evolving with investigational agents.

FAQs

1. What other conditions could Tagraxofusp-erzs potentially treat?
It is under investigation for other CD123-expressing malignancies, such as acute myeloid leukemia, though no approvals have been granted.

2. How does the drug's cost compare internationally?
Pricing varies, with the U.S. listing at around $23,000 per infusion. European prices tend to be lower but depend on negotiation and reimbursement decisions.

3. What are the main adverse effects of Elzonris?
Capillary leak syndrome, hepatotoxicity, and hematologic toxicity are most common, but generally manageable with monitoring.

4. Could biosimilars threaten its market exclusivity?
Unlikely before 2030 due to patent protection and high barriers to biosimilar development for such complex biologics.

5. Are there ongoing clinical trials for new indications?
Yes, trials are exploring use in other hematologic malignancies, but none have yet led to new approvals.

References

1. Fournier, E. et al. (2021). Incidence and diagnosis of blastic plasmacytoid dendritic cell neoplasm: A population-based study. Leukemia & Lymphoma, 62(2), 448-457.

2. FDA. (2018). FDA approves Elzonris for rare blood disorder. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov

3. EMA. (2020). European Commission approves Elzonris for BPDCN. European Medicines Agency. Retrieved from https://www.ema.europa.eu

4. Red Book. (2023). Drug pricing data. Micromedex.

5. Wang, E. et al. (2019). Clinical activity of tagraxofusp in BPDCN: A phase II trial. Blood, 134(3), 233-240.